细胞遗传学和基因突变影响接受阿扎胞苷或传统治疗的老年急性髓系白血病患者的生存
在3期AZA-AML-001研究中,老年初诊急性髓系白血病(AML)患者接受阿扎胞苷75 mg/m2/天×7天(n=240)或传统治疗方案(CCR;n=245)。对于欧洲白血病网(ELN)定义的不良核型患者,阿扎胞苷较CCR显著改善总生存(HR 0.71 [95%CI 0.51-0.99];P=0.046),且伴-5/5q-、-7/7q-或17p异常或单体/复杂核型者死亡风险降低31-46%。阿扎胞苷可能是伴不良细胞遗传学风险老年AML患者的首选治疗。
要点
- ELN不良核型患者中,阿扎胞苷较CCR显著改善总生存(HR 0.71;P=0.046)。
- 伴-5/5q-、-7/7q-、17p异常或单体/复杂核型者,阿扎胞苷组死亡风险降低31-46%。
- TP53或NRAS突变者CCR组总生存显著缩短;FLT3或TET2突变者阿扎胞苷组总生存显著缩短。
核心结论
- 阿扎胞苷可能是伴不良细胞遗传学风险老年AML患者的首选治疗,尤其是伴5、7和/或17号染色体异常及复杂或单体核型者。
- 基因突变对阿扎胞苷治疗患者的影响需进一步研究。
研究设计与样本
- 3期AZA-AML-001研究,纳入初诊老年AML患者,入组时评估细胞遗传学异常,部分患者评估基因突变。
- 患者接受阿扎胞苷75 mg/m2/天×7天(n=240)或传统治疗方案(CCR;n=245),CCR包括强化化疗、低剂量阿糖胞苷或仅最佳支持治疗。
主要发现
- 对于ELN定义的不良核型患者,阿扎胞苷较CCR显著改善总生存(HR 0.71 [95%CI 0.51-0.99];P=0.046)。
- 阿扎胞苷组伴-5/5q-、-7/7q-或17p异常,或伴单体或复杂核型者,较CCR死亡风险降低31-46%。
- 最常见的基因突变为DNMT3A(27%)、TET2(25%)、IDH2(23% [R140,15%;R172,8%])和TP53(21%)。
- 与野生型相比,CCR组伴TP53或NRAS突变者总生存显著缩短,阿扎胞苷组伴FLT3或TET2突变者总生存显著缩短。
临床怎么用
- 作者认为,阿扎胞苷可能是伴不良细胞遗传学风险老年AML患者的首选治疗,尤其是伴5、7和/或17号染色体异常及复杂或单体核型者。
局限性
- 基因突变对阿扎胞苷治疗患者的影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyotype (HR 0.71 [95%CI 0.51-0.99]; P = 0.046). Azacitidine-treated patients with -5/5q-, -7/7q-, or 17p abnormalities, or with monosomal or complex karyotypes, had a 31-46% reduced risk of death vs CCR. The most frequent gene mutations were DNMT3A (27%), TET2 (25%), IDH2 (23% [R140, 15%; R172, 8%]), and TP53 (21%). Compared with wild-type, OS was significantly reduced among CCR-treated patients with TP53 or NRAS mutations and azacitidine-treated patients with FLT3 or TET2 mutations. Azacitidine may be a preferred treatment for older patients with AML with Adverse-risk cytogenetics, particularly those with chromosome 5, 7, and/or 17 abnormalities and complex or monosomal karyotypes. The influence of gene mutations in azacitidine-treated patients warrants further study.
引用
- Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018. PMID: 30275526. doi:10.1038/s41375-018-0257-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。